The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome. (Q39386812)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

B Lamprecht

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

S Kreher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

W Sterry

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

B Dörken

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

M Janz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

C Assaf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

S Mathas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

language of work or name

English

0 references

publication date

6 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Dermatology

24 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

240-246

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

WHO-EORTC classification for cutaneous lymphomas

24 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Mycosis fungoides and Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Novel and highly recurrent chromosomal alterations in Sézary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Genomic loss of the putative tumor suppressor gene E2A in human lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

MYC and Aggressive B-cell Lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Analysis of p53 and mdm-2 expression in 18 patients with Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

p53 polymorphisms: cancer implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.10918.X

10.1111/J.1365-2133.2012.10918.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22384858%20AND%20SRC:MED&resulttype=core&format=json